BRAF p61BRAF(V600E)

CI-VAR-00005040Explore in graph →CIViC 3512

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma2
BRAF p61BRAF(V600E)	Vemurafenib	Predictive	C	Supports Resistance	2	submitted	EID9703 A 62 year old male with melanoma was treated with vemurafenib and achieved PFS of 148 days and 47% tumor reduction. Upon progression tumor samples were assessed for mutations in BRAF and NRAS by PCR. … (full text at CIViC) PMID 22113612 · Poulikakos et al., 2011 · Open in CIViC	civic
BRAF p61BRAF(V600E)	Vemurafenib	Predictive	D	Supports Resistance	4	submitted	EID9702 In an in vitro study, SKMEL-239 cells were exposed to 2uM vemurafenib for 2 months. Five independent cell lines were recovered and assessed for resistance alterations. Three cell lines expressing p61B… (full text at CIViC) PMID 22113612 · Poulikakos et al., 2011 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.